Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 13 studies | 24% ± 9% | |
glutamatergic neuron | 7 studies | 35% ± 19% | |
neuron | 6 studies | 22% ± 5% | |
interneuron | 5 studies | 30% ± 17% | |
endothelial cell of lymphatic vessel | 4 studies | 25% ± 4% | |
GABAergic neuron | 4 studies | 39% ± 13% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 6 studies | 30% ± 11% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 3444.27 | 2642 / 2642 | 100% | 24.57 | 702 / 705 |
adrenal gland | 74% | 458.78 | 190 / 258 | 80% | 12.23 | 185 / 230 |
thymus | 100% | 1161.88 | 652 / 653 | 52% | 1.99 | 315 / 605 |
kidney | 98% | 830.87 | 87 / 89 | 53% | 3.79 | 478 / 901 |
breast | 99% | 1563.52 | 453 / 459 | 30% | 0.94 | 333 / 1118 |
lung | 100% | 2372.51 | 578 / 578 | 17% | 0.58 | 191 / 1155 |
uterus | 99% | 1089.61 | 168 / 170 | 10% | 0.40 | 44 / 459 |
adipose | 100% | 1652.01 | 1202 / 1204 | 0% | 0 | 0 / 0 |
esophagus | 72% | 494.98 | 1044 / 1445 | 25% | 0.77 | 45 / 183 |
heart | 93% | 693.89 | 804 / 861 | 0% | 0 | 0 / 0 |
bladder | 81% | 556.76 | 17 / 21 | 9% | 0.30 | 43 / 504 |
prostate | 81% | 531.98 | 199 / 245 | 5% | 0.13 | 24 / 502 |
intestine | 67% | 423.66 | 650 / 966 | 10% | 0.37 | 51 / 527 |
spleen | 76% | 435.26 | 182 / 241 | 0% | 0 | 0 / 0 |
stomach | 47% | 231.45 | 168 / 359 | 27% | 0.94 | 76 / 286 |
ovary | 35% | 189.87 | 63 / 180 | 35% | 2.11 | 150 / 430 |
skin | 32% | 163.41 | 585 / 1809 | 22% | 1.24 | 105 / 472 |
pancreas | 12% | 49.88 | 40 / 328 | 34% | 1.83 | 61 / 178 |
blood vessel | 40% | 256.56 | 529 / 1335 | 0% | 0 | 0 / 0 |
muscle | 35% | 147.98 | 284 / 803 | 0% | 0 | 0 / 0 |
liver | 8% | 38.68 | 19 / 226 | 6% | 0.18 | 24 / 406 |
eye | 0% | 0 | 0 / 0 | 4% | 0.17 | 3 / 80 |
peripheral blood | 0% | 0.38 | 1 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0000398 | Biological process | mRNA splicing, via spliceosome |
GO_0030182 | Biological process | neuron differentiation |
GO_0120163 | Biological process | negative regulation of cold-induced thermogenesis |
GO_0051252 | Biological process | regulation of RNA metabolic process |
GO_0000381 | Biological process | regulation of alternative mRNA splicing, via spliceosome |
GO_1902667 | Biological process | regulation of axon guidance |
GO_0021954 | Biological process | central nervous system neuron development |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_1990825 | Molecular function | sequence-specific mRNA binding |
GO_0003729 | Molecular function | mRNA binding |
GO_0003723 | Molecular function | RNA binding |
Gene name | NOVA2 |
Protein name | NOVA alternative splicing regulator 2 (Neuro-oncological ventral antigen 2) NOVA alternative splicing regulator 2 NOVA2 [amino acids 1-28] RNA-binding protein Nova-2 (Astrocytic NOVA1-like RNA-binding protein) (Neuro-oncological ventral antigen 2) |
Synonyms | hCG_20810 ANOVA NOVA3 |
Description | FUNCTION: Functions to regulate alternative splicing in neurons by binding pre-mRNA in a sequence-specific manner to activate exon inclusion or exclusion . It binds specifically to the sequences 5'-YCAY-3' and regulates splicing in only a subset of regulated exons . Binding to an exonic 5'-YCAY-3' cluster changes the protein complexes assembled on pre-mRNA, blocking U1 snRNP binding and exon inclusion, whereas binding to an intronic 5'-YCAY-3' cluster enhances spliceosome assembly and exon inclusion. With NOVA1, they perform unique biological functions in different brain areas and cell types. Uniquely regulates alternative splicing events of a series of axon guidance related genes during cortical development, being essential for central nervous system development by regulating neural networks wiring. Regulates differentially alternative splicing on the same transcripts expressed in different neurons. This includes functional differences in transcripts expressed in cortical and cerebellar excitatory versus inhibitory neurons where is required for, respectively, development of laminar structure and motor coordination and synapse formation. Also the regulation the regulation of intron retention can sequester the trans-acting splicing factor PTBP2, acting as a variable cis-acting scaffolding platform for PTBP2 across various natural conditions (By similarity). . |
Accessions | ENST00000596784.1 Q9UNW9 A0A6Q8PFC2 ENST00000676183.1 M0R1A0 ENST00000263257.6 Q9HDB7 |